

International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,¹ notice is hereby given that the following names are under consideration by the World Health Organization

as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date

of their publication in the *WHO Chronicle*.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.


Proposed International Nonproprietary Names (Prop. INN): List 36²

*Proposed International
Nonproprietary Name (Latin, English)*

*Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number*


acidum pidolicum
pidolic acid

5-oxoproline
C₅H₇NO₃ 98-79-3



adamexinum
adamexine

α -(1-adamantylmethylamino)-4', 6'-dibromo-*o*-acetotoluidide
C₂₀H₂₆Br₂N₂O 54785-02-3



¹ See Annex 1, p. 25.

² Other lists of proposed international nonproprietary names can be found in *Chron. Wild Health Org.*, 1953, 7, 299; 1954, 8, 216, 313; 1956, 10, 28; 1957, 11, 231; 1958, 12, 102; *WHO Chronicle*, 1959, 13, 105, 152; 1960, 14, 168, 244; 1961, 15, 314; 1962, 16, 385; 1963, 17, 389; 1964, 18, 433; 1965, 19, 446; 1966, 20, 216; 1967, 21, 70, 478; 1968, 22, 112, 407; 1969, 23, 183, 418; 1970, 24, 119, 413; 1971, 25, 123, 415; 1972, 26, 121, 414; 1973, 27, 120, 330; 1974, 28, 133; supplements to *WHO Chronicle*, 1974, Vol. 28, No. 9; 1975, Vol. 29, No. 3, No. 9; 1976, Vol. 30, No. 3.


Lists of recommended international nonproprietary names were published in *Chron. Wild Health Org.*, 1955, 9, 185; *WHO Chronicle*, 1959, 13, 106, 463; 1962, 16, 101; 1965, 19, 165, 206, 249; 1966, 20, 421; 1967, 21, 538; 1968, 22, 463; 1969, 23, 490; 1970, 24, 526; 1971, 25, 476; 1972, 26, 476; 1973, 27, 453; supplements to *WHO Chronicle*, 1974, Vol. 28, No. 10; 1975, Vol. 29, No. 10.

Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*. Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw. fr. 6.—); an account of this publication will be found on page 18 of this Supplement (Annex 2). All names from Lists 1-25 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: World Health Organization, *International Nonproprietary Names for Pharmaceutical Substances. Cumulative list No. 3, 1971*. Geneva, 1971 (price: Sw. fr. 24.—).

These publications may be obtained from the sales agents listed on the back cover of the *WHO Chronicle* or from: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.


alifluranum
aliflurane

2-chloro-1,2,3,3-tetrafluorocyclopropyl methyl ether
 $C_4H_3ClF_4O$ 56689-41-9




amezinii metilsulfas
amezinium metilsulfate

4-amino-6-methoxy-1-phenylpyridazinium methyl sulfate
 $C_{12}H_{15}N_3O_5S$ 30578-37-1




amineptinum
amineptine

7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid
 $C_{22}H_{27}NO_2$ 57574-09-1




amitriptylinoxidum
amitriptylinoxide

10,11-dihydro-N,N-dimethyl-5H-dibenzo[a,d]cycloheptene- $\Delta^{5,\gamma}$ -propylamine
N-oxide
 $C_{20}H_{23}NO$ 4317-14-0




amoscanatum
amoscanate

p-(p-nitroanilino)phenyl isothiocyanate
 $C_{13}H_9N_3O_2S$ 26328-53-0




azelastinum
azelastine

4-(*p*-chlorobenzyl)-2-(hexahydro-1-methyl-1*H*-azepin-4-yl)-1(2*H*)-phthalazinone
C₂₂H₂₄ClN₃O 58581-89-8




azepindolum
azepindole

2,3,4,5-tetrahydro-1*H*-[1,4]diazepino[1,2-*a*]indole
C₁₂H₁₄N₂ 26304-61-0




azipraminum
azipramine

1-[2-(benzylmethylamino)ethyl]-6,7-dihydroindolo[1,7-*ab*][1]benzazepine
C₂₆H₂₆N₂ 58503-82-5




azlocillinum
azlocillin

(2*S*,5*R*,6*R*)-3,3-dimethyl-7-oxo-6-[(*R*)-2-(2-oxo-1-imidazolidinylcarboxamido)-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
C₂₀H₂₃N₅O₆S 37091-66-0




benzoxonii chloridum
benzoxonium chloride

benzylododecylbis(2-hydroxyethyl)ammonium chloride
C₂₃H₄₂ClNO₂ 19379-90-9




belarizinium
belarizine

α -[4-(diphenylmethyl)-1-piperazinyl]- p -cresol
C₂₄H₂₈N₂O 52395-99-0




bevantololum
bevantolol

1-[(3,4-dimethoxyphenethyl)amino]-3-(*m*-tolylloxy)-2-propanol
C₂₀H₂₇NO₄ 59170-23-9




budipinum
budipine

1-*tert*-butyl-4,4-diphenylpiperidine
C₂₁H₂₇N 57982-78-2



buserelinum
buserelin

5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-*O*-*tert*-butyl-D-seryl-L-leucyl-L-arginyl-*N*-ethyl-L-prolinamide
C₆₀H₈₆N₁₆O₁₃ 57982-77-1




*Proposed International
Nonproprietary Name (Latin, English)*

*Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number*


carazololum
carazolol

1-(carbazol-4-yloxy)-3-(isopropylamino)-2-propanol
C₁₈H₂₂N₂O₂ 57775-29-8




hoprostum
hoprost

(*E,Z*)-(1*R*,2*R*,3*R*,5*S*)-7-[3,5-dihydroxy-2-[(3*S*)-(3-hydroxy-3-methyl-1-octenyl)]cyclopentyl]-5-heptenoic acid
C₂₃H₃₆O₅ 35700-23-3




carbutamidum
carbutamide

1-butyl-3-sulfanylylurea
C₁₁H₁₇N₃O₃S 339-43-5




carcainii chloridum
carcainium chloride

dimethylbis[(phenylcarbamoyl)methyl]ammonium chloride
C₁₈H₂₂ClN₃O₂ 1042-42-8




carnitinum
carnitine

(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt
C₇H₁₅NO₃ 461-06-3




cefaclorum
cefaclor

(6*R*,7*R*)-7-[(*R*)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C₁₅H₁₄ClN₃O₄S 53994-73-3




cefazaflurum
cefazaflur

(6*R*,7*R*)-3-[[1-methyl-1*H*-tetrazol-5-yl]thio]methyl]-8-oxo-7-[2-[(trifluoromethyl)thio]acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C₁₃H₁₃F₃N₆O₄S₃ 58665-96-6




cefazedonum
cefazedone

(6*R*,7*R*)-7-[2-(3,5-dichloro-4-oxo-1(4*H*)-pyridyl)acetamido]-3-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C₁₈H₁₅Cl₂N₅O₅S₃ 56187-47-4




cethxonii chloridum
cethxonium chloride

hexadecyl(2-hydroxycyclohexyl)dimethylammonium chloride
C₂₄H₅₀ClNO 58703-78-9




cetraxatum
cetraxate

p-hydroxyhydrocinnamic acid *trans*-(4-aminomethyl)cyclohexanecarboxylate
C₁₇H₂₃NO₄ 34675-84-8




chloralosum
chloralose

α -chloralose or (*R*)-1,2-*O*-(2,2,2-trichloroethylidene)- α -D-glucofuranose
 $C_8H_{11}Cl_3O_6$ 15879-93-3




clindolum
clindole

3-(dimethylamino)-1,2,3,4-tetrahydrocarbazole
 $C_{14}H_{18}N_2$ 32211-97-5




cicloheximidum
cicloheximide

3-[(*R*)-2-[(1*S*,3*S*,5*S*)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl-
glutarimide
 $C_{15}H_{23}NO_4$ 66-81-9




ciprafamidum
cprafamide

N-(*cis*-2,*trans*-3-diphenylcyclopropyl)-1-pyrrolidineacetamide
 $C_{21}H_{24}N_2O$ 35452-73-4




ciprofibratum
ciprofibrate

2-[*p*-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropionic acid
 $C_{13}H_{14}Cl_2O_3$ 52214-84-3




cloasantelum
cloasatel

5'-chloro- α^4 -(*p*-chlorophenyl)- α^4 -cyano-3,5-diiodo-2',4'-salicyloxylicide
C₂₂H₁₄Cl₂I₂N₂O₂ 57808-65-8




cloximatum
cloximate

2-(dimethylamino)ethyl (*E*)-[[(*p*-chloro- α -methylbenzylidene)amino]oxy]-
acetate
C₁₄H₁₉ClN₂O₃ 58832-68-1




cogazocinum
cogazocine

3-(cyclobutylmethyl)-6-ethyl-1,2,3,4,5,6-hexahydro-11,11-dimethyl-2,6-
methano-3-benzazocin-8-ol
C₂₁H₃₁NO 57653-29-9




colterolum
colterol

(±)- α -[(*tert*-butylamino)methyl]-3,4-dihydroxybenzyl alcohol
C₁₂H₁₉NO₃ 18866-78-9




cropropamidum
cropropamide

N-[1-(dimethylcarbamoyl)propyl]-*N*-propylcrotonamide
C₁₃H₂₄N₂O₂ 633-47-6




crotetamidum
crotetamide

N-[1-(dimethylcarbamoyl)propyl]-*N*-ethylcrotonamide
C₁₂H₂₂N₂O₂ 6168-76-9




difeterolum
difeterol

α -[1-[[2-(diphenylmethoxy)ethyl]methylamino]ethyl]benzyl alcohol
C₂₅H₂₉NO₂ 14587-50-9




domperidonum
domperidone

5-chloro-1-[1-[3-(2-oxo-1-benzimidazolyl)propyl]-4-piperidyl]-2-benzimidazolinone
C₂₂H₂₄ClN₅O₂ 57808-66-9




drinidenum
drinidene

2-(aminomethylene)-1-indanone
C₁₀H₉NO 53394-92-6




droprenilaminum
droprenilamine

N-(3,3-diphenylpropyl)- α -methylcyclohexaneethylamine
C₂₄H₃₃N 57653-27-7




droxacinum
droxacin

5-ethyl-2,3,5,8-tetrahydro-8-oxofuro[2,3-*g*]quinoline-7-carboxylic acid
C₁₄H₁₃NO₄ 35067-47-1




elfazepamum
elfazepam

7-chloro-1-[2-(ethylsulfonyl)ethyl]-5-(*o*-fluorophenyl)-1,3-dihydro-2*H*-1,4-
benzodiazepin-2-one
C₁₉H₁₈ClFN₂O₃S 52042-01-0




etoperidonum
etoperidone

1-[3-[4-(*m*-chlorophenyl)-1-piperazinyl]propyl]-3,4-diethyl-4,5,6,7-tetrahydro-1,2,4-
triazolin-5-one
C₁₉H₂₈ClN₅O 52942-31-1




femoxetinum
femoxetine

(+)-*trans*-3-[(*p*-methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine
C₂₀H₂₅NO₂ 59859-58-4



fenobamum
fenobam

1-(*m*-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolin-2-yl)urea
C₁₁H₁₁ClN₄O₂ 57653-26-6




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


fludiazepamum
fludiazepam

7-chloro-5-(*o*-fluorophenyl)-1,3-dihydro-1-methyl-2*H*-1,4-benzodiazepin-2-one
C₁₆H₁₂ClFN₂O 3900-31-0




trimezadolum
trimezadol

2-(*o*,*o*,*o*-trifluoro-*m*-tolyl)morpholine
C₁₁H₁₂F₃NO 30914-89-7



framycetinum
framycetin

neomycin B or *O*-2,6-diamino-2,6-dideoxy- β -L-idopyranosyl-(1 \rightarrow 3)-*O*- β -D-ribofuranosyl-(1 \rightarrow 5)-*O*-[2,6-diamino-2,6-dideoxy- α -D-glucopyranosyl-(1 \rightarrow 4)]-2-deoxy-D-streptamine
C₂₃H₄₆N₆O₁₃ 119-04-0




gleptoferrinum
gleptoferron

(dextran)(glucoheptonic acid)hydroxyoxoiron
approx. FeOOH [(C₆H₁₀O₅)_n · C₇H₁₄O₈] 57680-55-4


guanfacinum
guanfacine

N-amidino-2-(2,6-dichlorophenyl)acetamide
C₉H₉Cl₂N₃O 29110-47-2




halopredonum
halopredone

2-bromo-6 β ,9-difluoro-11 β ,17,21-trihydroxypregna-1,4-diene-3,20-dione
C₂₁H₂₅BrF₂O₅ 57781-15-4




homidii bromidum
homidium bromide

3,8-diamino-5-ethyl-6-phenylphenanthridinium bromide
C₂₁H₂₀BrN₃ 1239-45-8




ibazocinum
ibazocine

1,2,3,4,5,6-hexahydro-6,11,11-trimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol
C₂₀H₂₉NO 57653-28-8




imipraminoxidum
imipraminoxide

5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine N-oxide
C₁₉H₂₄N₂O 6829-98-7




impacarzium
impacarzine

N,N-diethyl-4-[2-(2-oxo-3-tetradecyl-1-imidazolidinyl)ethyl]-1-piperazine-carboxamide
C₂₈H₅₅N₅O₂ 41340-39-0




iproheptinum
iproheptine

N-isopropyl-1,5-dimethylhexylamine
C₁₁H₂₅N 13946-02-6




iprozilaminum
iprozilamine

4-chloro-2-(isopropylamino)-6-(4-methyl-1-piperazinyl)-5-(methylthio)-
pyrimidine
C₁₃H₂₂ClN₅S 55477-19-5




isamoxolum
isamoxole

N-butyl-2-methyl-*N*-(4-methyl-2-oxazolyl)propionamide
C₁₂H₂₀N₂O₂ 57067-46-6




isoflupredonom
isoflupredone

9-fluoro-11 β ,17,21-trihydroxypregna-1,4-diene-3,20-dione
C₂₁H₂₇FO₅ 338-95-4




isosulpridum
isosulpride

1-ethyl-5'-sulfamoyl-2-pyrrolidineacet-*o*-anisidide
C₁₅H₂₃N₃O₄S 42792-26-7




lofendazamum
lofendazam

8-chloro-1,3,4,5-tetrahydro-1-phenyl-2H-1,5-benzodiazepin-2-one
 $C_{15}H_{13}ClN_2O$ 29176-29-2




lopirazepamum
lopirazepam

7-chloro-5-(*o*-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-pyrido[3,2-*e*]-1,4-diazepin-2-one
 $C_{14}H_9Cl_2N_3O_2$ 42863-81-0




menfegolum
menfegol

α -[*p*-(*p*-menthyl)phenyl]- ω -hydroxypoly(oxyethylene)
 $(C_2H_4O)_n C_{16}H_{24}O$ 57821-32-6




mepindololum
mepindolol

1-(isopropylamino)-3-[(2-methylindol-4-yl)oxy]-2-propanol
 $C_{15}H_{22}N_2O_2$ 23694-81-7




meseclazonum
meseclazone

7-chloro-3,3a-dihydro-2-methyl-2H,9H-isoxazolo[3,2-*b*][1,3]benzoxazin-9-one
 $C_{11}H_{10}ClNO_3$ 29053-27-8




mezilaminum
mezilamine

4-chloro-2-(methylamino)-6-(4-methyl-1-piperazinyl)-5-(methylthio)-
pyrimidine
 $C_{11}H_{13}ClN_5S$ 50335-55-2




moprololum
moprotol

1-(isopropylamino)-3-(*o*-methoxyphenoxy)-2-propanol
 $C_{13}H_{21}NO_3$ 5741-22-0




moxaverinum
moxaverine

1-benzyl-3-ethyl-6,7-dimethoxyisoquinoline
 $C_{20}H_{21}NO_2$ 10539-19-2




netilmicinum
netilmicin

O-3-deoxy-4-*C*-methyl-3-(methylamino)- β -*L*-arabinopyranosyl(1 \rightarrow 4)-*O*-
[2,6-diamino-2,3,4,6-tetra-deoxy- α -*D*-glycero-hex-4-enopyranosyl-(1 \rightarrow 6)]-
2-deoxy-*N*³-ethyl-*L*-streptamine
 $C_{21}H_{41}N_5O_7$ 56391-56-1




nifurtinolum
nifurtinol

3-(hydroxymethyl)-1-[(5-nitrofurfurylidene)amino]hydantoin
 $C_9H_9N_4O_6$ 1088-92-2




nifuroquinum
nifuroquine

4-(5-nitro-2-furyl)quinaldic acid 1-oxide
C₁₄H₈N₂O₆ 57474-29-0




nocodazolum
nocodazole

methyl 5-(2-thenoyl)-2-benzimidazolecarbamate
C₁₄H₁₁N₃O₃S 31430-18-9




oxepinacum
oxepinac

6,11-dihydro-11-oxodibenz[*b,e*]oxepin-3-acetic acid
C₁₆H₁₂O₄ 55689-65-1




oxitropii bromidum
oxitropium bromide

(8*r*)-6β,7β-epoxy-8-ethyl-3α-hydroxy-1αH,5αH-tropanium bromide (-)-tropate
C₁₉H₂₆BrNO₄ 30286-75-0




pamatololum
pamatolol

methyl (±)-[*p*-[2-hydroxy-3-(isopropylamino)propoxy]phenethyl]carbamate
C₁₆H₂₆N₂O₄ 59110-35-9




pargololum
pargolol

1-(*tert*-butylamino)-3-[*o*-(2-propynyloxy)phenoxy]-2-propanol
C₁₆H₂₃NO₃ 47082-97-3




penirololum
penirolol

o-[2-hydroxy-3-(*tert*-pentylamino)propoxy]benzotrile
C₁₅H₂₂N₂O₂ 58503-83-6




polyestradioli phosphas
polyestradiol phosphate

estradiol phosphate polymer
approx. (C₁₈H₂₂)_m(O₄P)_n 28014-46-2




in which -R- is




prefenamatum
prefenamate

3-methyl-2-butenyl *N*-(α,α,α -trifluoro-*m*-tolyl)anthranilate
C₁₉H₁₈F₃NO₂ 57775-28-7




procodazololum
procodazole

2-benzimidazolepropionic acid
C₁₀H₁₀N₂O₂ 23249-97-0




quazepamum
quazepam

7-chloro-5-(*o*-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-thione
C₁₇H₁₁ClF₄N₂S 36735-22-5




ropizinium
ropizine

1-(diphenylmethyl)-4-[[[6-methyl-2-pyridyl]methylene]amino]piperazine
C₂₄H₂₆N₄ 3601-19-2




rosoxicinum
rosoxicin

1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid
C₁₇H₁₄N₂O₃ 40034-42-2




sarpicillinum
sarpicillin

methoxymethyl (2*S*,5*R*,6*R*)-6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
C₂₁H₂₇N₃O₅S 40966-79-8




sermetacinum
sermetacin

N-[[1-(*p*-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]-L-serine
C₂₂H₂₁ClN₂O₆ 57645-05-3




setazindolum
setazindol

4'-chloro-2-[(methylamino)methyl]benzhydrol
C₁₅H₁₆ClNO 56481-43-7




silibininum
silibinin

3,5,7-trihydroxy-2-[2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl]-1,4-benzodioxan-6-yl]-4-chromanone
C₂₅H₂₂O₁₀ 22888-70-6




silicristinum
silicristin

2-[2,3-dihydro-7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-5-benzofuranyl]-3,5,7-trihydroxy-4-chromanone
C₂₅H₂₂O₁₀ 33889-69-9




silidianinum
silidianin

(+)-2,3 α ,3a α ,7a-tetrahydro-7a α -hydroxy-8-(4-hydroxy-3-methoxyphenyl)-4-(3 α ,5,7-trihydroxy-4-oxo-2 β -chromanyl)-3,6-methanobenzofuran-7(6 α H)-one
C₂₅H₂₂O₁₀ 29782-68-1




succisulfonum
succisulfone

4'-sulfanilylsuccinanilic acid
C₁₆H₁₆N₂O₅S 5934-14-5




suclofenidum
suclofenide

3-chloro-4-(phenylsuccinimido)benzenesulfonamide
C₁₆H₁₃ClN₂O₄S 30279-49-3




sufentanilum
sufentanil

N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]propionanilide
C₂₂H₃₀N₂O₂S 56030-54-7




sufosfamidum
sufosfamide

2-[[3-(2-chloroethyl)tetrahydro-2*H*-1,3,2-oxazaphosphorin-2-yl]amino]-ethanol methanesulfonate (ester) *P*-oxide
C₈H₁₈ClN₂O₅PS 37753-10-9



sulfiramum
sulfiram

bis(diethylthiocarbamoyl) sulfide
C₁₀H₂₀N₂S₃ 95-05-6




sulodexidum
sulodexide

glucorono-2-amino-2-deoxyglucoglucan sulfate
57821-29-1

sulprosalum
sulprosal

salicylic acid ester with 3-hydroxy-1-propanesulfonic acid
C₁₀H₁₂O₆S 58703-77-8




teprotidum
teprotide

5-oxo-L-prolyl-L-tryptophyl-L-prolyl-L-arginyl-L-prolyl-L-glutamyl-L-
isoleucyl-L-prolyl-L-proline
C₅₃H₇₅N₁₄O₁₂ 35115-60-7

H-5-oxo-L-Pro-L-Trp-L-Pro-L-Arg-L-Pro-L-Gln-
-L-Ile-L-Pro-L-Pro-OH


thenyldiaminum
thenyldiamine

2-[[2-(dimethylamino)ethyl]-3-thenylamino]pyridine
C₁₄H₁₉N₃S 91-79-2




tiodonii chloridum
tiodonium chloride

(*p*-chlorophenyl)-2-thienyliodonium chloride
C₁₀H₇Cl₂S 38070-41-6




tiopropaminum
tiopropamine

3,3-diphenyl-3'-(phenylthio)dipropylamine
C₂₄H₂₇NS 39516-21-7




tocainidum
tocainide

2-amino-2',6'-propionoxylidide
C₁₁H₁₆N₂O 41708-72-9




toliodii chloridum
toliodium chloride

di-*p*-tolyliodonium chloride
C₁₄H₁₄ClI 19028-28-5




tolmesoxidum
tolmesoxide

4,5-dimethoxy-2-(methylsulfinyl)toluene
C₁₀H₁₄O₃S 38452-29-8




treptilaminum
treptilamine

2-[(α -tricyclo[2.2.1.0^{2,6}]hept-3-ylidenebenzyl)oxy]triethylamine
C₂₀H₂₇NO 58313-74-9




triamcinoloni benetonidum
triamcinolone benetonide

9-fluoro-11 β ,16 α ,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic
16,17-acetal with acetone 21-ester with *N*-benzoyl-2-methyl- β -alanine
C₃₅H₄₂FNO₈ 31002-79-6




triamcinoloni furetonidum
triamcinolone furetonide

9-fluoro-11 β ,16 α ,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic
16,17-acetal with acetone, 21-(2-benzofurancarboxylate)
C₃₃H₃₅FO₈ 4989-94-0




ubisindinum
ubisindine

2-[2-(diethylamino)ethyl]-3-phenylphthalimidine
C₂₀H₂₄N₂O 26070-78-0




valofanum
valofane

(3-allyltetrahydro-5-methyl-2-oxo-3-furoyl)urea
C₁₀H₁₄N₂O₄ 3258-51-3




vinpocetinum
vinpocetine

ethyl apovincamin-22-oate
C₂₂H₂₆N₂O₂ 42971-09-5




gabamum
gabam

1-(1-methyl-2-pyrrolidinylidene)-3-(2,6-xylol)urea
C₁₄H₁₉N₃O 50528-97-7




zimelidinum
zimelidine

(Z)-3-[1-(p-bromophenyl)-3-(dimethylamino)propenyl]pyridine
C₁₅H₁₇BrN₂ 56775-88-3



zotepinum
zotepine

2-[(8-chlorodibenzo[*b,f*]thiepin-10-yl)oxy]-*N,N*-dimethylethylamine
C₁₈H₁₉ClNOS 26615-21-4




AMENDMENTS TO PREVIOUS LISTS

Supplement to Vol. 30, No. 3

Proposed International Nonproprietary Names (Prop. INN): List 35


p. 2 alrestatinum
ancitabinum

replace -CONa in the graphic formula by -COONa
replace the graphic formula by the following :



p. 10 narasinum

replace the chemical name (first part) and graphic formula by the following :
 α -ethyl-6-[5-[2-(5-.....



For the names listed below the Chemical Abstracts Service (CAS) registry numbers should be replaced by the following

p. 1 acidum diprogulicum	18467-77-1
p. 5 butoctamidum	32838-26-9
p. 11 picafibratum	57548-79-5
p. 14 tizolemidum	56488-58-5

International Nonproprietary Names for Pharmaceutical Substances: Cumulative List No. 3, 1971

p. 79 delete

medigoxinum
medigoxin

insert

metildigoxinum
metildigoxin

Annex 1

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES *

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA3.11 :

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*¹ and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration

B. Such notice shall:

(i) set forth the name under consideration;

(ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;

(iii) identify the substance for which a name is being considered;

(iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

(v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

A. Such objection shall:

(i) identify the person objecting;

(ii) state his interest in the name;

(iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name.

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the nonproprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1969, 173, 10).

¹ The title of this publication was changed to *WHO Chronicle* in January 1959.

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided.

These primary principles are to be implemented by using the following secondary principles

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g.,

"oxacillin" and "oxacillin sodium",
"ibufenac" and "ibufenac sodium".

5. INN for substances that are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the inactive base.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate

components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, "f" should be used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of

"y"; the use of the letters "h" and "k" should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see

Guiding Principle 2) should if possible be shown by using a stem from the following list. The stem should only be used for substances of the appropriate group. Where a stem is shown without any hyphens it may be used anywhere in the name.

Subsidiary group relationships should be shown by devising INN that show similarities to and are analogous with a previously named substance.

Latin	English	French
-actidum	-actide	-actide
andr	andr	andr
-arolum	-arol	-arol
-azepamum	-azepam	-azépam
bol	bol	bol
-buzonium	-buzone	-buzone
-cainum	-caine	-caine
cef-	cef-	céf-
-cillinum	-cillin	-cilline
cort	cort	cort
-cyclinum	-cycline	-cycline
estr	estr	estr
-fibratum	-fibrate	-fibrate
-forminum	-formin	-formine
gest	gest	gest
gli-	gli-	gli-
io-	io-	io-
-ium	-ium	-ium
-metacinum	-metacin	-métacine
-mycinum	-mycin	-mycine
-nidazolium	-nidazole	-nidazole
-ololum	-olol	-olol
-onidium	-onide	-onide
-orexum	-orex	-orex
-praminum	-pramine	-pramine
-profenum	-profen	-profène
prost	prost	prost
-relinum	-relin	-réline
sulfa-	sulfa-	sulfa-
-terolum	-terol	-térol
-tizidium	-tizide	-tizide
-verinum	-verine	-vérine

synthetic polypeptides with a corticotrophin-like action
steroids, androgens
anticoagulants of the dicoumarol group
substances of the diazepam group
steroids, anabolic
anti-inflammatory analgesics of the phenylbutazone group
local anaesthetics
antibiotics, derivatives of cephalosporanic acid
antibiotics, derivatives of 6-aminopenicillanic acid
corticosteroids, except those of the prednisolone group
antibiotics of the tetracycline group
estrogenic substances
substances of the clofibrate group
hypoglycemics of the phenformin group
steroids, progestogens
sulfonamide hypoglycemics
iodine-containing contrast media
quaternary ammonium compounds
anti-inflammatory substances of the indometacin group
antibiotics, produced by *Streptomyces* strains
antiprotozoal substances of the metronidazole group
 β -adrenergic blocking agents of the propranolol group
steroids for topical use, containing an acetal group
anorexigenic agents, phenethylamine derivatives
substances of the imipramine group
anti-inflammatory substances of the ibuprofen group
prostaglandins
hypophyseal hormone release-stimulating peptides
sulfonamides, anti-infective
bronchodilators, phenethylamine derivatives
diuretics of the chlorothiazide group
spasmolytics with a papaverine-like action

Annex 2

NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES: TWENTIETH REPORT OF THE WHO EXPERT COMMITTEE

In its twentieth report¹ the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, international nonproprietary names (INN) in the light of developments in pharmaceutical compounds in recent years. The most significant recent change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves employing a characteristic "stem" indicative of a common property of the members of a group. The reasons for, and the implications of, the change are fully

discussed. Also reported is the intention to change the practice with regard to the nomenclature of individual members of polymeric series.

Other sections of the report concern instructions to be followed by bodies making application for international nonproprietary names, the availability of computer-printed cumulative lists of international nonproprietary names, information supplied by WHO Member States concerning their official use of national or international names for pharmaceutical products, and proposals relative to the withdrawal of international nonproprietary names allocated to substances that are no longer in use.

The official texts relating to the procedures for selecting, and general

guidance for devising, international nonproprietary names are reproduced in two annexes to the report. Other annexes give examples of international nonproprietary names that incorporate selected stems, the most frequently used initial groups of letters in international nonproprietary names, a historical review of the programme of selecting international nonproprietary names, some useful literature references, and a model of the form to be used in all applications for international nonproprietary names.

¹ WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*, Twentieth Report of the WHO Expert Committee), ISBN 92.4.120581.4. Price: Sw. fr. 6.—.